- Conditions
- Hypertension
- Interventions
- Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Patients, Resistant Hypertension
- Interventions
- LHW090, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Tezosentan
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Houston, Texas
- Conditions
- Hypertension
- Interventions
- Minocycline
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- High Blood Pressure
- Interventions
- Nebivolol, Metoprolol XL
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
- Interventions
- standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet
- Dietary Supplement
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Equivalent dose enalapril, Equivalent dose lisinopril
- Drug
- Lead sponsor
- Memorial Health University Medical Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Hypertension
- Interventions
- Darusentan, Guanfacine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 661 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more
- Conditions
- Obesity, Metabolic Syndrome X
- Interventions
- Metformin, Orlistat, Topiramate, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Hypertension
- Interventions
- Darusentan, Darusentan Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
- Conditions
- Hypertension
- Interventions
- Darusentan, Guanfacine, Darusentan Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
- Conditions
- Hypertension
- Interventions
- Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
- Drug · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
- Interventions
- Yoga lifestyle intervention, Standard of care
- Behavioral · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
- Interventions
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Device · Drug
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Interventions
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
- Device · Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Duluth, Minnesota
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Minocycline Hydrochloride, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Renal Artery Stenosis, Hypertension, Renovascular
- Interventions
- iCAST™ Rx Stent System
- Device
- Lead sponsor
- Atrium Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more
- Conditions
- Hypertension
- Interventions
- Enhanced External Counterpulsation
- Device
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertension, Uncontrolled Hypertension, Hypertension, White Coat, Hypertension, Resistant to Conventional Therapy
- Interventions
- Blood pressure measurement device
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hyperkalemia, Resistant Hypertension
- Interventions
- Patiromer, Placebo, Spironolactone
- Drug
- Lead sponsor
- Relypsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
- Drug · Radiation
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania